Sponsors (11)
The bill strengthens federal oversight and inspection funding to improve safety and consistency of compounded and prescription drugs, but does so at the cost of higher compliance fees, administrative burdens, potential supply disruptions, and reduced access to customized compounded medications for some patients.
Patients (including those with chronic conditions) and health systems will likely see safer, more consistent compounded and prescription drugs because the bill prioritizes FDA-manufactured products, increases monitoring of high-volume compounders, requires registration, and funds inspections.
Hospitals and health systems will gain greater assurance about the quality of compounded products (and reduced inpatient reporting burden) because in‑state hospital pharmacies are exempt and large-scale outsourcing facilities face registration and routine FDA inspections.
Federal and state health regulators will obtain better data and more flexible tools to detect and address high-volume compounding risks because of reporting requirements and Secretary authority to monitor and set fees that fund inspection and oversight activities.
Patients with unique, rare, or chronic needs may lose access to customized compounded medications because of the 20-per-month cap, reporting thresholds, and outreach by compounders to avoid compliance burdens, causing some compounders to stop serving certain patients or out‑of‑State orders.
Small compounding pharmacies and local outsourcing facilities will face significant new compliance, reporting, inspection, and fee costs that can threaten viability, reduce local access, or force business closures.
Patients could face higher out-of-pocket costs if compounded alternatives become less available or if increased fees and compliance costs are passed through to prices for specialized medications.
Based on analysis of 5 sections of legislative text.
Introduced December 9, 2025 by Rudy Yakym · Last progress December 9, 2025
Places limits and new oversight on compounding of drugs that duplicate commercially available products: it caps how often pharmacies can make ‘‘copies,’’ requires annual reporting when compounding for out-of-state patients exceeds a monthly threshold, creates inspection and registration rules for high-volume outsourcing facilities, and gives the FDA discretion to set establishment fees to fund safety activities. The bill defines what counts as a commercial product and an ‘‘essentially a copy’’ compounded product, and phases in inspection and registration changes within six months while reporting begins for calendar year 2025.